Fingerprint
Dive into the research topics of 'Brief report: A phase II "window-of-opportunity" frontline study of the mTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically